CMPS Total Utang marang Modal COMPASS Corp

The confirmed price history on the chart shows that the total debt-to-equity ratio for COMPASS Pathways plc (CMPS) is 0.60. COMPASS Pathways plc develops psychopharmaceutical drugs based on psilocybin and is currently in an investment stage without a stable cash flow. The strategy relies on multi-profile clinical trials to minimize bureaucratic risks, while operational activities are based on strict ESG standards for the eco-friendly processing of chemicals and the use of ethical raw materials.

This ratio compares the company's total liabilities to its equity. A decrease in this metric confirms growing financial autonomy, whereas an increase signals over-leverage. By analyzing the dynamics of financial dependence, an investor assesses the balance between debt leverage and asset stability. For COMPASS Pathways plc (CMPS), this parameter is critical when scaling the COMP360 platform. An optimal debt level ensures the development of a closed therapy ecosystem without the risk of insolvency.